X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock Has Consensus Price Target of $11.25 According to Analysts

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) have been given an average recommendation of “Moderate Buy” by the six ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $11.25.

XFOR has been the subject of a number of research analyst reports. Weiss Ratings upgraded X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Wells Fargo & Company assumed coverage on shares of X4 Pharmaceuticals in a research report on Friday, July 10th. They issued an “overweight” rating and a $11.00 price objective for the company.

X4 Pharmaceuticals Stock Up 3.6%

Shares of XFOR stock opened at $3.18 on Monday. X4 Pharmaceuticals has a one year low of $2.43 and a one year high of $4.83. The company has a quick ratio of 11.02, a current ratio of 11.30 and a debt-to-equity ratio of 0.49. The stock has a 50-day moving average of $3.23 and a 200-day moving average of $3.78.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.01. The company had revenue of $2.88 million during the quarter, compared to analysts’ expectations of $2.78 million. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. Analysts anticipate that X4 Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other X4 Pharmaceuticals news, Chairman Adam Craig sold 47,436 shares of X4 Pharmaceuticals stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $210,615.84. Following the sale, the chairman owned 328,651 shares in the company, valued at $1,459,210.44. The trade was a 12.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, President John Volpone sold 24,576 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $109,117.44. Following the sale, the president directly owned 265,305 shares in the company, valued at $1,177,954.20. This trade represents a 8.48% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 83,779 shares of company stock valued at $353,387. 1.13% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in XFOR. Russell Investments Group Ltd. increased its holdings in X4 Pharmaceuticals by 2,871.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 213,258 shares of the company’s stock valued at $618,000 after purchasing an additional 206,080 shares during the period. Alps Advisors Inc. boosted its position in X4 Pharmaceuticals by 36.2% in the third quarter. Alps Advisors Inc. now owns 130,424 shares of the company’s stock valued at $378,000 after buying an additional 34,698 shares during the last quarter. WINTON GROUP Ltd increased its stake in X4 Pharmaceuticals by 35.8% during the 2nd quarter. WINTON GROUP Ltd now owns 14,400 shares of the company’s stock worth $67,000 after buying an additional 3,800 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in X4 Pharmaceuticals in the second quarter valued at $313,000. Finally, AXQ Capital LP acquired a new stake in X4 Pharmaceuticals in the second quarter valued at approximately $107,000. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company’s research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.

X4’s lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.